DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics, Corp. (GSD) a leading supplier of products and services to the medical diagnostic industry today announced the launch of an extended partnership with Fujirebio Diagnostics, Inc. to distribute their proprietary Cyfra 21-1 EIA assays in the U.S. Market. Fujirebio, known best in the US market as the developers of the CA125 ovarian cancer marker, have a number of patents on biomarkers for various disease states, but are primarily focused on oncology markers. GSD also is distributor of Fujirebio’s HE4 EIA, Multi-Constituent Tumor Marker control and Vitamin D control.
